Anika Therapeutics Reports Third-Quarter Loss per Share

Anika Therapeutics reported third-quarter 2026 revenue of $30.6 million, up 10% year over year, and gross margin of 62%. The company recorded a $0.3 million loss from continuing operations and adjusted diluted earnings per share of $0.29. Anika raised the lower end of its 2026 revenue growth guidan…